Drug news
Pfizer files rLP2086 vaccine at FDA for Meningococcal disease ,
Pfizer Inc. announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bivalent recombinant LP2086 (rLP2086), the company�s vaccine candidate for the prevention of invasive Meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.